HRP20211392T1 - INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA - Google Patents
INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA Download PDFInfo
- Publication number
- HRP20211392T1 HRP20211392T1 HRP20211392TT HRP20211392T HRP20211392T1 HR P20211392 T1 HRP20211392 T1 HR P20211392T1 HR P20211392T T HRP20211392T T HR P20211392TT HR P20211392 T HRP20211392 T HR P20211392T HR P20211392 T1 HRP20211392 T1 HR P20211392T1
- Authority
- HR
- Croatia
- Prior art keywords
- membered
- group
- compound
- formula
- image
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 52
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- 150000002431 hydrogen Chemical class 0.000 claims 31
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 21
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical group 0.000 claims 15
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 14
- -1 hydroxy, sulfhydryl Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 13
- 229910052805 deuterium Inorganic materials 0.000 claims 13
- 229910052731 fluorine Inorganic materials 0.000 claims 13
- 239000011737 fluorine Substances 0.000 claims 13
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 12
- 229910052801 chlorine Inorganic materials 0.000 claims 12
- 239000000460 chlorine Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 11
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000005110 aryl thio group Chemical group 0.000 claims 10
- 125000004104 aryloxy group Chemical group 0.000 claims 10
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 10
- 125000005368 heteroarylthio group Chemical group 0.000 claims 10
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 10
- 125000004468 heterocyclylthio group Chemical group 0.000 claims 10
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000004470 heterocyclooxy group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 102200048928 rs121434568 Human genes 0.000 claims 1
- 102200048955 rs121434569 Human genes 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol:
[image]
pri čemu:
prsten A je:
[image]
Q je veza,; R je vodik;
X1, X2 i X3 su svaki neovisno odabrani iz skupine koja sadrži NR7 i CR8, pri čemu najmanje jedan od X1, X2 i X3 je NR7;
R1 je odabran iz skupine koja sadrži:
[image]
pri čemu tri R6 u
[image]
su opcionalno jednaki ili različiti supstituenti;
R2 je odabrana iz skupine koja sadrži C1-8 alkil i C3-8 cikloalkil, pri čemu C1-8 alkil i C3-8 cikloalkil su opcionalno supstituirani jednom ili više skupina odabranih iz skupine koja sadrži halogen, hidroksi, C1-8 alkil, C1-8 alkoksi, halo C1-8alkoksi, C3-8 cikloalkil i C3-8 cikloalkoksi;
R3 je odabran iz skupine koja sadrži vodik, deuterij, halogen, cijano, nitro, C1-8 alkil, C1-8 alkoksi, C3-8 cikloalkil, trifluorometil, trifluorometoksi, SOL2R9, C(O)R10, C(O)OR10 i P(O)R11R12;
R4 je odabran iz skupine koja sadrži vodik, deuterij, halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, 3- do 8-člani heterocikliloksi, 3-do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5- do 10-člani heteroaril, 5- do 10-člai heteroariloksi, 5- do 10-člani heteroariltio, -C0-8-P(O)R11R12, -C0-8-S(O)rR9, -C0-8-O-R10, -C0-8-C(O)R10, -C0-8-C(O)OR10, -C0-8-O-C(O)R10, -C0-8-NR7R8, -C0-8-C(O)NR7R8, -N(R7)-C(O)R10 i -N(R7)-C(O)OR10,
pri čemu C1-8 alkil, C3-8 cikloalkil, 3- do 8-člani heterociklil, C5-10 aril, 5- do 10- člani heteroaril, 5- do 7-člani karbocikl, 5-do 7-člani heterocikl, C5-7 aril i 5- do 7-člani heteroaril su svaki opcionalno supstituirani jednom ili više skupina odabranih iz skupine koja sadrži halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, 3- do 8-člani heterocikliloksi, 3- do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5- do 10-člani heteroaril, 5- do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, -C0-8-S(O)rR9, -C0-8-O- R10, -C0-8-C(O) R10,-C0-8-C(O)OR10,-C0-8-O-C(O)R10,-C0-8-NR7R8,-C0-8-C(O) NR7R8, -N(R7)-C(O) R10 i -N(R7)-C(O)O R10;
R6 je odabran iz skupine koja sadrži vodik, deuterij, C1-8 alkil, halo C1-8alkil i C(O)R10;
R7 je odabran iz skupine koja sadrži vodik, deuterij, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, C5-10 aril, 5- do 10-člani heteroaril, - C0-8-S(O)rR9, - C0-8-C(O)R10,
pri čemu C1-8 alkil ako je supstituiran, supstituiran je s jednom ili više skupina odabranih iz skupine koja sadrži halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3- do 8- člani heterociklil, 3-do 8-člani heterocikliloksi, 3- do 8-člani heterocikliltio, C5-10 aril, C5-10ariloksi, C5-10 ariltio, 5- do 10-člani heteroaril, 5- do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, - C0-8-S(O)rR9, - C0-8-O- R10, - C0-8-C(O) R10, - C0-8-C(O)O R10, - C0-8-O-C(O) R10, - C0-8-NR7R8, - C0-8-C(O)NR7R8, -N(R7)-C(O) R10 i -N(R7)-C(O)O R10; C3-8 cikloalkil, 3- do 8-člani heterociklil, C5-10 aril i 5-do 10- člani heteroaril su svaki opcionalno supstituirani jednom ili više skupina odabranih iz skupine koja sadrži halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8alkinil, C3-8 cikloalkil, 3- do 8-člani heterociklil, 3-do 8-člani heterocikliloksi, 3-do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5-do 10-člani heteroaril, 5-do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, - C0-8-S(O)rR9, - C0-8-O- R10, - C0-8-C(O) R10, - C0-8-C(O)O R10,- C0-8-O-C(O) R10, - C0-8-NR7R8, - C0-8-C(O)N R7R8, -N(R7)-C(O) R10 i -N(R7)-C(O)O R10;
R8 je odabran iz skupine koja sadrži vodik, deuterij, halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, 3- do 8-člani heterocikliloksi, 3- do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5- do 10- člani heteroaril, 5- do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, -C0-8-S(O)rR9, -C0-8-O- R10, -C0-8-C(O) R10, -C0-8-C(O)O R10, -C0-8-O-C(O) R10, -C0-8-NR7R8, -C0-8-C(O)NR7R8, -N(R7)-C(O)R10 i -N(R7)-C(O)O R10,
pri čemu C1-8 alkil, C3-8 cikloalkil, 3- do 8-člani heterociklil, C5-10 aril, 5- do 10-člani heteroaril su svaki opcionalno supstituirani jednom ili više skupina odabranim iz skupine koja sadrži halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, 3- do 8-člani heterocikliloksi, 3- do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5- do 10-člani heteroaril, 5- do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, - C0-8-S(O)rR9, - C0-8-O- R10, - C0-8-C(O) R10, - C0-8-C(O)O R10, - C0-8-O-C(O) R10, - C0-8-NR7R8, - C0-8-C(O)N R7R8, -N(R7)-C(O) R10 i -N(R7)-C(O)O R10;
R9 je odabran iz skupine koja sadrži vodik, deuterij, C1-8 alkil, C3-8 cikloalkil, halo C1-8 alkil, bis- C1-8 alkilamino, fenil i p-metilfenil;
R10, R11 i R12 su svaki neovisno odabrani iz skupine koja sadrži vodik, deuterij, C1-8 alkil, C3-8 cikloalkil, haloC1-8 alkil i hidroksiC1-8 alkil; m je 0, 1, 2, 3 ili 4;
r je 0, 1 ili 2;
q je 0, 1, 2, 3 ili 4; i
"
[image]
" znači da supstituent R može biti Z ili E konfiguracija,
pri čemu ako R7 je odabran iz skupine koja sadrži vodik, deuterij, ili nesupstituirani C1-8 alkil, tada je spoj odabran iz skupine koja sadrži:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
2. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, pri čemu R2 je odabran iz skupine koja sadrži C1-4 alkil i C3-6 cikloalkil, pri čemu C1-4 alkil i C3-6 cikloalkil su svaki opcionalno supstituirani jednom ili više skupina odabranih iz skupine koja sadrži halogen, hidroksi, C1-8 alkil, C1-8 alkoksi, haloC1-8 alkoksi, C3-8 cikloalkil i C3-8 cikloalkoksi; prsten A, Q, R, X1, X2 i X3, R1, R3, R4, R6, R7, R8, R9, R10, R11, R12,, m, r i q su kao što je opisano u patentnom zahtjevu 1, poželjno pri čemu R2 je odabran iz skupine koja sadrži C1-4 alkil i C3-6 cikloalkil, pri čemu C1-4 alkil i C3-6 cikloalkil su svaki opcionalno supstituirani jednom ili više skupina odabranih iz skupine koja sadrži halogen i hidroksi; prsten A, Q, R, X1, X2 i X3, R1, R3, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisao u patentnom zahtjevu 1, još poželjnije pri čemu R2 je C1-4 alkil opcionalno supstituiran jednom ili više skupina odabranih iz skupine koja sadrži fluor ili hidroksi; prsten A, Q, R, X1, X2 i X3, R1, R3, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, još poželjnije
pri čemu je R2 odabran iz skupine koja sadrži metil, difluorometil i trifluorometil; prsten A, Q, R, X1, X2 i X3, R1, R3, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, najpoželjnije pri čemu je to spoj neki spoj formule (IA):
[image]
pri čemu R2 je odabran iz skupine koja sadrži metil, difluorometil i trifluorometil; prsten A, R, X1, X2 i X3, R1, R3, R4, R6, R7, R8, R9, R10, R11, m, r i q su kao što je opisano u patentnom zahtjevu 1; ili pri čemu je spoj odabran iz skupine sastavljene od spoja formule (IIA1) i spoj formule (IIA2):
[image]
pri čemu R2 je odabran iz skupine koja sadrži metil, difluorometil i trifluorometil; prsten A, R, X1, X2 i X3, R1, R3, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1; ili
pri čemu je to spoj odabran iz skupine koja sastoji se od spoja formule (IIIA1-1), spoj formule (IIIA1-2), spoj formule (IIIA1-3), spoj formule (IIIA1-4), spoj formule (IIIA1-5) i spoj formule (IIIA1-6):
[image]
pri čemu R2 je odabran iz skupine koja sadrži metil, difluorometil i trifluorometil; R, R1, R3, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1; ili
pri čemu je spoj odabran iz skupine sastavljene od spoja formule (IVA1-1) i spoja formule (IVA1-2):
[image]
pri čemu R, R1, R3, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, poželjno pri čemu R3 je odabran iz skupine koja sadrži vodik, deuterij, halogen, C1-8 alkil, C1-8 alkoksi, C3-8 cikloalkil, trifluorometil i trifluorometoksi; R, R1, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, ili pri čemu R3 je odabran iz skupine koja sadrži vodik, fluor, klor, metil, etil, izopropil, metoksi, etoksi, izopropoksi, ciklopropil, ciklobutil, trifluorometil i trifluorometoksi; R, R1, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q je kao što je opisano u patentnom zahtjevu 1; poželjno, R3 je odabran iz skupine koja sadrži vodik, fluor, klor, metil, ciklopropil i trifluorometil.
3. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 2, pri čemu je to spoj odabran iz skupine koja sadrži:
[image]
4. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 2, pri čemu je taj spoj neki spoj formule (IVA1-3):
[image]
pri čemu R, R1, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, poželjno pri čemu R, R1, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, pod uvjetom da kada R8 je vodik, m je 2, 3 ili 4; kada R8 nije vodik, m je 1, 2, 3 ili 4, ili
pri čemu R3 je odabran iz skupine koja sadrži vodik, fluor, klor, metil, ciklopropil i trifluorometil; R, R1, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, pod uvjetom da kada je R8 vodik, m je 2, 3 ili 4; kada R8 nije vodik, m je 1, 2, 3 ili 4, ili kada spoj je odabran iz skupine koja sadrži:
[image]
ili
Pri čemu, kada m je 2, 3 ili 4, R3 je odabran iz skupine koja sadrži vodik, fluor, klor, metil, ciklopropil i trifluorometil; dva R4 su uzeta zajedno s atomim ugljika spojenih benzen prstena da bi oformio 5-do 7-člani karbocikl, 5-do 7-člani heterocikl, C5-7 aril ili 5- do 7-člani heteroaril, odabran iz skupine koja sadrži:
[image]
pri čemu 5 do 7-člani karbocikl, 5- do 7-člani heterocikl, C5-7 aril i 5- do 7-člani heteroaril su svaki opcionalno supstituirani jednom ili više skupina odabranih iz skupine koja sadrži halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, 3- do 8-člani heterocikliloksi, 3- do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5- do 10-člani heteroaril, 5- do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, -C0-8-S(O)rR9, -C0-8-O-R10, -C0-8-C(O)R10, -C0-8-C(O)OR10, -C0-8-O-C(O)R10, -C0-8-NR7R8, -C0-8-C(O)NR7R8, -N(R7)-C(O)R10 i -N(R7)-C(O)OR10;
R, R1, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1.
5. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 4, pri čemu, kada je vodik, m je 0 ili 1; kada R8 nije vodik, m je 0, 1 ili 2; R3 je odabran iz vodika, fluora, klora, metila, ciklopropila i trifluorometila;
R4 je odabran iz skupine koja sadrži vodik, deuterij, halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, 3- do 8-člani heterocikliloksi, 3- do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5- do 10- člani heteroaril, 5- do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, -C0-8-P(O)R11R12, -C0-8-S(O)rR9, -C0-8-O-R10, -C0-8-C(O)R10, -C0-8-C(O)OR10, -C0-8-O-C(O)R10, -C0-8-NR7R8, -C0-8-C(O)NR7R8, -N(R7)-C(O)R10 i -N(R7)-C(O)OR10;
pri čemu C1-8 alkil, C3-8 cikloalkil, 3- do 8-člani heterociklil, C5-10 aril, 5- do 10- člani heteroaril, 5- do 7-člani karbocikl, 5-do 7-člani heterocikl, C5-7 aril i 5- do 7-člani heteroaril su svaki opcionalno supstituirani jednom ili više skupina odabranim iz skupine koja sadrži halogen, hidroksi, sulfidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, 3- do 8-člani heterocikliloksi, 3- do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5- do 10-člani heteroaril, 5- do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, - C0-8-S(O)rR9, - C0-8-O- R10, - C0-8-C(O)R10, - C0-8-C(O)OR10, - C0-8-O-C(O)R10, - C0-8-N R7R8, - C0-8-C(O)NR7R8, -N(R7)-C(O)R10 i -N(R7)-C(O)OR10;
R, R1, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1.
6. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 5, pri čemu R3 je odabran iz skupine koja sadrži vodik, fluor, klor i trifluorometil; R4 je odabran iz skupine koja sadrži vodik, deuterij, halogen, hidroksi, sulfhidril, cijano, nitro, azido, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3-do 8-člani heterociklil, 3- do 8-člani heterocikloksi, 3- do 8-člani heterocikliltio, C5-10 aril, C5-10 ariloksi, C5-10 ariltio, 5-do 10-člani heteroaril, 5-do 10-člani heteroariloksi, 5- do 10-člani heteroariltio, - C0-8-S(O)rR9, - C0-8-O- R10, - C0-8-C(O)R10, - C0-8-C(O)OR10, - C0-8-O-C(O)R10, - C0-8-N R7R8, - C0-8-C(O)NR7R8, -N(R7)-C(O)R10 i -N(R7)-C(O)OR10;
R, R1, R4, R6, R7, R8, R9, R10, R11, R12, r i q su kao što je opisano u patentnom zahtjevu 1; i m je kao što je opisano u patentnom zahtjevu 5, ili
pri čemu R3 je odabran iz skupine koja sadrži vodik, fluor, klor, i trifluorometil; R4 je odabran Iz skupine koja sadrži vodik, deuterij, hidroksi, cijano, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, 3- do 8-člani heterociklil, 3- do 8-člani heterocikliloksi, C5-10 aril,C5-10 ariloksi, 5- do 10-člani heteroaril, 5- do 10-člani heteroariloksi, -C0-8-O-R10, -C0-8-C(O)OR10, -C0-8-O-C(O)R10, -C0-8-NR7R8 i -C0-8-C(O)N R7R8;
R, R1, R4, R6, R7, R8, R9, R10, R11, R12 i q su kao što je opisano u patentnom zahtjevu 1; i m je kao što je opisano u patentnom zahtjevu 5, ili
pri čemu R3 je odabran iz skupine koja sadrži vodik, fluor, klor, i trifluorometil; R4 je odabran iz skupine koja sadrži vodik, deuterij, hidroksi, cijano, etenil, etinil, ciklopropil, ciklobutil, oksetan- 3-il, N-R6-azetidin-3-il, ciklopropoksi, ciklobutiloksi, fenil, fenoksi, - C0-8-O-R10, - C0-8-C(O)OR10, - C0-8-O-C(O)R10, - C0-8-N R7R8 i - C0-8-C(O)N R7R8;
R, R1, R4, R6, R7, R8, R9, R10, R11, R12 i q su kao što je opisano u patentnom zahtjevu 1; i m je kao što je opisano u patentnom zahtjevu 5, ili pri čemu je spoj odabran iz skupine koja sadrži:
[image]
[image]
[image]
7. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 2, pri čemu je to spoj odabran iz skupine sastavljene od spoja formule (IIIA1-7), spoj formule (IIIA1-8) i spoj formule (IIIA1-9):
[image]
pri čemu R2 je odabran iz skupine koja sadrži metil, difluorometil i trifluorometil; R, R, R1, R4, R6, R7, R8, R9, R10, R11, m, r i q su kao što je opisano u patentnom zahtjevu 1.
8. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 7, pri čemu R2 je odabran iz skupine koja sadrži metil, difluorometil i trifluorometil; R3 je odabran iz skupine koja sadrži vodik, fluor, klor i trifluorometil; R, R1, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, poželjno pri čemu R1 je odabran iz skupine koja sadrži
[image]
još poželjnije pri čemu spoj je odabran iz skupine sastavljene od spoja formule (IVA1-4) i spoj formule (IVA1-5):
[image]
pri čemu R3 je odabran iz skupine koja sadrži vodik, fluor, klor i trifluorometil; R, R4, R6, R7, R8, R9, R10, R11, R12, m i r su kao što je opisano u patentnom zahtjevu 1, i još poželjnije pri čemu je pripravak odabran pod uvjetom da se sastoji od
[image]
[image]
[image]
[image]
9. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 7, pri čemu je to spoj odabran iz skupine koja sastavljene od spoja formule (IVA1-6) i spoja formule (IVA1-7):
[image]
pri čemu R3 je odabran iz skupine koja sadrži vodik, fluor, klor i trifluorometil; R, R4, R6, R7, R8, R9, R10, R11, R12, m i r su kao što je opisano u patentnom zahtjevu 1, poželjno pri čemu je pripravak odabran pod uvjetom da se sastoji od
[image]
[image]
[image]
10. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 2, pri čemu je to spoj odabran iz skupine sastavljene od spoja formule (IIIA2-1), spoja formule (IIIA2-2), spoja formule (IIIA2-3), spoja formule (IIIA2-4), spoja formule (IIIA2-5) spoja formule (IIIA2-6):
[image]
pri čemu R2 je odabran is skupine koja sadrži metil, difluorometil i trifluorometil; R, R1, R3, R4, R6, R7, R8, R9, R10, R11,R12, m, r i q su kao što je opisano u patentnom zahtjevu 1, poželjno pri čemu R3 je odabran iz skupine koja sadrži vodik, fluor, klor i trifluorometil; R, R1, R3, R4, R6, R7, R8, R9, R10, R11,R12 m, r i q su kao što je opisano u patentnom zahtjevu 1, još poželjnije pri čemu R1 je
[image]
11. Postupak za dobivanje spoja formule (I), ili stereoizmera ili njegove farmaceutski prihvatljive soli sukladno bilo kojem od patentnih zahtjeva 1 do 10, sadrži korake:
[image]
pri čemu prsten A, Q, X1, X2 i X3, R1, R2,R3, R4, R6, R7, R8, R9, R10, R11, R12, m, r i q su kao što je opisano u patentnom zahtjevu 1.
12. Farmaceutski pripravak koji sadrži terapeutski učinkovitu količinu spojeva formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno bilo kojem od patentnih zahtjeva 1 do 11, i farmaceutski prihvatljiv nosač.
13. Spoj formule (I), ili stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno bilo kojem od patentnih zahtjeva 1 do 10, ili farmaceutski pripravak sukladno patentnom zahtjevu 12 za uporabu u liječenje bolesti uzrokovane aktivnošću EGFR mutanta i aktivnost mutanta aktivirana putem eksolna 19 brisanja, poželjno, pri čemu je taj EGFR mutant odabran iz skupine koja sadrži EGFR- L858R mutant i EGFR-T790M pri čemu spoj formule (I), stereoizomer ili njegova farmaceutski prihvatljiva sol sukladno bilo kojem od patentnih zahtjeva 1 do 10, ili farmaceutski pripravak sukladno patentnom zahtjevu 12 je za uporabu kao lijeka u liječenju karcinoma, poželjno pri čemu je karcinom odabran iz skupine koja sadrži karcinom jajnika, karcinom grlića maternice, kolorektalni karcinom, karcinom dojke, karcinom gušterače, gliom, glioblastom, melanom, karcinom prostate, leukemiju, limfom, non-Hodgkinov limfom, karcinom želuca, karcinom pluća, hepatocelularni karcinom, karcinom želuca, gastrointestinalni stromalni tumor (GIST), karcinom štitnjače, kolangiokarcinom, karcinom endometrija, karcinom bubrega, anaplastični limfom velike stanice, akutna mijeloična leukemija (AML), multipli mijelom, melanom i mezoteliom, poželjno nemalostanični karcinom pluća.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410534203 | 2014-10-11 | ||
| EP15849629.9A EP3205650B1 (en) | 2014-10-11 | 2015-09-30 | Egfr inhibitor, and preparation and application thereof |
| PCT/CN2015/091189 WO2016054987A1 (zh) | 2014-10-11 | 2015-09-30 | Egfr抑制剂及其制备和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211392T1 true HRP20211392T1 (hr) | 2021-12-10 |
Family
ID=55652583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211392TT HRP20211392T1 (hr) | 2014-10-11 | 2021-09-01 | INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10259820B2 (hr) |
| EP (1) | EP3205650B1 (hr) |
| JP (1) | JP6691281B2 (hr) |
| KR (1) | KR102589982B1 (hr) |
| CN (7) | CN117050062A (hr) |
| AU (1) | AU2015330506B2 (hr) |
| BR (1) | BR112017006713B1 (hr) |
| CA (1) | CA2959194A1 (hr) |
| CY (1) | CY1124476T1 (hr) |
| DK (1) | DK3205650T3 (hr) |
| ES (1) | ES2886887T3 (hr) |
| HR (1) | HRP20211392T1 (hr) |
| HU (1) | HUE055233T2 (hr) |
| LT (1) | LT3205650T (hr) |
| MX (1) | MX2017004234A (hr) |
| PL (1) | PL3205650T3 (hr) |
| PT (1) | PT3205650T (hr) |
| RS (1) | RS62350B1 (hr) |
| RU (1) | RU2702631C2 (hr) |
| SI (1) | SI3205650T1 (hr) |
| TW (1) | TWI704138B (hr) |
| WO (1) | WO2016054987A1 (hr) |
| ZA (1) | ZA201701465B (hr) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40240B1 (fr) | 2014-06-19 | 2019-03-29 | Ariad Pharma Inc | Composés hétéroaryle d'inhibition de la kinase |
| CN105384694B (zh) * | 2014-08-22 | 2020-09-04 | 四川海思科制药有限公司 | 一种取代的氨基嘧啶衍生物及其制备方法和药物用途 |
| CN111170998B (zh) * | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| WO2016105525A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| CN106117185B (zh) * | 2015-08-31 | 2017-11-07 | 广州必贝特医药技术有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
| CN106749193B (zh) * | 2015-11-23 | 2020-11-20 | 南京圣和药业股份有限公司 | 吲唑取代的表皮生长因子受体抑制剂及其应用 |
| CN106928150B (zh) * | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| TWI726968B (zh) | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| WO2017119732A1 (en) | 2016-01-08 | 2017-07-13 | Samsung Electronics Co., Ltd. | Electronic device and operating method thereof |
| US11753626B2 (en) | 2016-03-09 | 2023-09-12 | Beijing Percans Oncology Co., Ltd. | Tumor cell suspension cultures and related methods |
| CN112645933B (zh) * | 2016-03-22 | 2022-02-11 | 江苏豪森药业集团有限公司 | Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用 |
| CN107344934B (zh) * | 2016-05-04 | 2019-08-23 | 江苏正大丰海制药有限公司 | 药物活性物质的固体形式 |
| CN107417626B (zh) * | 2016-05-23 | 2020-01-24 | 江苏奥赛康药业有限公司 | 一种2-氨基嘧啶类化合物的多晶型形式 |
| AR110038A1 (es) * | 2016-05-26 | 2019-02-20 | Kalyra Pharmaceuticals Inc | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos |
| CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
| CN110818690B (zh) * | 2016-07-26 | 2021-08-10 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| CN107793413B (zh) * | 2016-09-05 | 2021-09-28 | 上海科州药物研发有限公司 | 嘧啶杂环化合物及其制备方法和应用 |
| CN109689657B (zh) * | 2016-09-19 | 2021-06-11 | 南京创特医药科技有限公司 | 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用 |
| CN107973783B (zh) * | 2016-10-21 | 2024-09-06 | 正大天晴药业集团股份有限公司 | 作为erk抑制剂的苯胺嘧啶衍生物 |
| CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
| CN108503627A (zh) * | 2017-04-19 | 2018-09-07 | 郑州泰基鸿诺医药股份有限公司 | 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用 |
| KR20200015595A (ko) * | 2017-06-02 | 2020-02-12 | 에프. 호프만-라 로슈 아게 | 화합물 |
| CA3071345A1 (en) * | 2017-07-28 | 2019-01-31 | Yale University | Anticancer drugs and methods of making and using same |
| EP3653622B1 (en) * | 2017-08-30 | 2022-12-28 | Shenzhen TargetRx, Inc. | Aminopyrimidine compound and composition comprising same and use thereof |
| CN109503573A (zh) * | 2017-09-14 | 2019-03-22 | 昆明圣加南生物科技有限公司 | 2-取代苯胺基嘧啶衍生物及其用途 |
| TWI702205B (zh) * | 2017-10-06 | 2020-08-21 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 表皮生長因子受體抑制劑 |
| CN108017633A (zh) * | 2018-01-30 | 2018-05-11 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用 |
| KR20190108079A (ko) * | 2018-03-13 | 2019-09-23 | 보로노이바이오 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN110272420A (zh) | 2018-03-16 | 2019-09-24 | 江苏正大丰海制药有限公司 | 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法 |
| AU2019269372A1 (en) | 2018-05-14 | 2020-11-26 | Takeda Pharmaceutical Company Limited | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders |
| CN110719782B (zh) * | 2018-05-15 | 2023-02-07 | 江苏豪森药业集团有限公司 | 包含第三代小分子egfr抑制剂的药物组合物及其制备方法 |
| CN111818925B (zh) * | 2018-05-23 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途 |
| CN110066272B (zh) * | 2018-05-29 | 2022-09-13 | 深圳市塔吉瑞生物医药有限公司 | 取代的苯并[d]咪唑类化合物及其药物组合物 |
| CN110652514A (zh) * | 2018-06-29 | 2020-01-07 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制药用途 |
| CN110698461B (zh) * | 2018-07-09 | 2024-04-05 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制备方法 |
| WO2020052575A1 (zh) * | 2018-09-12 | 2020-03-19 | 江苏恒瑞医药股份有限公司 | Jak激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途 |
| CN113773304B (zh) * | 2019-02-25 | 2023-03-10 | 江苏豪森药业集团有限公司 | 抗耐药抗肿瘤egfr抑制剂的制备方法 |
| CN111606889B (zh) * | 2019-02-25 | 2023-03-07 | 上海翰森生物医药科技有限公司 | 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法 |
| CN110041302B (zh) * | 2019-03-01 | 2021-11-30 | 南方医科大学 | 2-氨基-4-取代吡啶衍生物及其合成方法和应用 |
| KR102220624B1 (ko) * | 2019-03-15 | 2021-02-25 | 김민서 | 드라이 플라워의 처리 방법 및 드라이 플라워의 처리제 |
| CN115838369A (zh) | 2019-03-19 | 2023-03-24 | 株式会社沃若诺伊 | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| CN111747950B (zh) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
| EP3974423A4 (en) * | 2019-05-22 | 2023-06-21 | Shanghai Hansoh Biomedical Co., Ltd. | INHIBITOR CONTAINING AN INDOLE DERIVATIVE, METHOD FOR PREPARING IT AND ITS USE |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| CN110183399A (zh) * | 2019-06-05 | 2019-08-30 | 辽宁科隆精细化工股份有限公司 | 一种合成4-(2-(n,n-二甲氨基)乙基)吗啉的方法 |
| CN114008028B (zh) * | 2019-06-20 | 2024-07-09 | 昂科比克斯有限公司 | 抑制癌细胞生长的嘧啶衍生物及其医药用途 |
| CN110684016A (zh) * | 2019-09-27 | 2020-01-14 | 上海应用技术大学 | 一种含氟的azd9291衍生物及其制备方法和应用 |
| KR102383200B1 (ko) * | 2019-10-18 | 2022-04-06 | 한국화학연구원 | 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| TW202128670A (zh) * | 2019-11-26 | 2021-08-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮多環類衍生物抑制劑、其製備方法和應用 |
| KR20220130190A (ko) | 2020-01-20 | 2022-09-26 | 아스트라제네카 아베 | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021180238A1 (zh) * | 2020-03-13 | 2021-09-16 | 郑州同源康医药有限公司 | 一类用作激酶抑制剂的化合物及其应用 |
| CN113493420A (zh) * | 2020-03-18 | 2021-10-12 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| WO2021243596A1 (en) * | 2020-06-03 | 2021-12-09 | InventisBio Co., Ltd. | Aminopyrimidine compounds, preparation methods and uses thereof |
| TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
| WO2022105882A1 (zh) * | 2020-11-19 | 2022-05-27 | 上海翰森生物医药科技有限公司 | 一种含吲哚类衍生物的盐、晶型及其制备方法和应用 |
| WO2022131741A1 (ko) * | 2020-12-14 | 2022-06-23 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| CN112457299B (zh) * | 2020-12-14 | 2021-12-17 | 江苏豪森药业集团有限公司 | Egfr抑制剂的纯化方法 |
| UY39600A (es) * | 2020-12-30 | 2022-05-31 | Biocad Joint Stock Co | Inhibidores del receptor del factor de crecimiento epidérmico |
| CN112679448B (zh) * | 2020-12-31 | 2022-08-19 | 苏州昊帆生物股份有限公司 | N-(2-氨基乙基)吗啉的制备方法 |
| CN117255792A (zh) * | 2021-05-07 | 2023-12-19 | 沃若诺伊公司 | 杂芳基衍生物、其制备方法以及包括其作为活性成分的药物组合物 |
| US20240252481A1 (en) * | 2021-05-14 | 2024-08-01 | Nanjing Chuangte Pharmaceutical Technology Co., Ltd. | Pharmaceutical formulations |
| BR112022024068A2 (pt) * | 2021-05-17 | 2023-12-05 | Voronoi Inc | Compostos de derivado de heteroarila e usos dos mesmos |
| CN113387935B (zh) * | 2021-07-23 | 2022-06-10 | 苏州雅深智慧科技有限公司 | 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途 |
| WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| TW202421146A (zh) | 2022-07-08 | 2024-06-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑與ｈｇｆ受體抑制劑的組合 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201510696RA (en) * | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| ES2659725T3 (es) * | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | Inhibidores de EGFR y procedimiento de tratamiento de trastornos |
| US20130137709A1 (en) * | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
| JP5999177B2 (ja) * | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| RS60190B1 (sr) * | 2011-07-27 | 2020-06-30 | Astrazeneca Ab | 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za lečenje raka |
| AU2013204563B2 (en) * | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| CA2917364C (en) * | 2013-07-11 | 2020-09-29 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| JP6468611B2 (ja) * | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| WO2015188777A1 (en) * | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
| MA40240B1 (fr) * | 2014-06-19 | 2019-03-29 | Ariad Pharma Inc | Composés hétéroaryle d'inhibition de la kinase |
| CN104140418B (zh) | 2014-08-15 | 2016-08-24 | 常州润诺生物科技有限公司 | 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途 |
| CN106458969A (zh) * | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
| CN105461695B (zh) * | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
| CN111170998B (zh) * | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| WO2016105525A2 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| US10329277B2 (en) * | 2015-07-16 | 2019-06-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity |
| CN106117185B (zh) * | 2015-08-31 | 2017-11-07 | 广州必贝特医药技术有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
-
2015
- 2015-09-30 KR KR1020177012005A patent/KR102589982B1/ko active IP Right Grant
- 2015-09-30 CN CN202311030017.7A patent/CN117050062A/zh active Pending
- 2015-09-30 RU RU2017114687A patent/RU2702631C2/ru active
- 2015-09-30 PT PT158496299T patent/PT3205650T/pt unknown
- 2015-09-30 AU AU2015330506A patent/AU2015330506B2/en active Active
- 2015-09-30 WO PCT/CN2015/091189 patent/WO2016054987A1/zh active Application Filing
- 2015-09-30 CN CN202311339167.6A patent/CN117402143A/zh active Pending
- 2015-09-30 PL PL15849629T patent/PL3205650T3/pl unknown
- 2015-09-30 MX MX2017004234A patent/MX2017004234A/es unknown
- 2015-09-30 EP EP15849629.9A patent/EP3205650B1/en active Active
- 2015-09-30 RS RS20211144A patent/RS62350B1/sr unknown
- 2015-09-30 CN CN201580045311.2A patent/CN106661000B/zh active Active
- 2015-09-30 BR BR112017006713-7A patent/BR112017006713B1/pt active IP Right Grant
- 2015-09-30 CA CA2959194A patent/CA2959194A1/en active Pending
- 2015-09-30 CN CN201910208542.0A patent/CN111170999B/zh active Active
- 2015-09-30 CN CN201910210386.1A patent/CN111171000B/zh active Active
- 2015-09-30 ES ES15849629T patent/ES2886887T3/es active Active
- 2015-09-30 CN CN202311029815.8A patent/CN117069700A/zh active Pending
- 2015-09-30 LT LTEPPCT/CN2015/091189T patent/LT3205650T/lt unknown
- 2015-09-30 US US15/517,193 patent/US10259820B2/en active Active
- 2015-09-30 DK DK15849629.9T patent/DK3205650T3/da active
- 2015-09-30 CN CN201910210387.6A patent/CN111187221B/zh active Active
- 2015-09-30 SI SI201531690T patent/SI3205650T1/sl unknown
- 2015-09-30 HU HUE15849629A patent/HUE055233T2/hu unknown
- 2015-09-30 JP JP2017517797A patent/JP6691281B2/ja active Active
- 2015-10-07 TW TW104133007A patent/TWI704138B/zh active
-
2017
- 2017-02-27 ZA ZA2017/01465A patent/ZA201701465B/en unknown
-
2018
- 2018-12-03 US US16/207,968 patent/US10428081B2/en active Active
-
2021
- 2021-09-01 HR HRP20211392TT patent/HRP20211392T1/hr unknown
- 2021-09-07 CY CY20211100794T patent/CY1124476T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211392T1 (hr) | INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA | |
| HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
| HRP20192209T1 (hr) | Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini | |
| DOP2016000339A (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo | |
| MX2018008168A (es) | Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia. | |
| PH12017502246B1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MD4575C1 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| PH12016500150A1 (en) | Quinoline derivative | |
| EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
| MD4490C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| PH12017502334A1 (en) | Polycyclic amide derivative as cdk9 inhibitors | |
| MD4779B1 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR067824A1 (es) | Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer. | |
| HRP20221018T1 (hr) | Liječenje katapleksije | |
| MX2016004964A (es) | Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo. | |
| PH12016500234A1 (en) | Tricyclic benzoxaborole compounds and uses thereof | |
| JP2013520443A5 (hr) | ||
| JP2015520770A5 (hr) | ||
| TW201613864A (en) | Novel compounds | |
| EA201692550A1 (ru) | Соединения, содержащие систему 1,1',2,5'-тетрагидроспиро[индол-3,2'-пиррол]-2,5'-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2 | |
| MX2019015888A (es) | Bifenil amidas con grupos eter modificados como inhibidores de hsp90 e inductores de hsp70. | |
| MX2015013224A (es) | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. | |
| EA201691046A1 (ru) | Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) | |
| RU2017107681A (ru) | Производные хиназолина |